GenomaCES Biotechnologies, a Spinoff from CES University, published an article on March 22 in the Frontiers in Genetics magazine, in conjunction with the Georgia Institute of Technology (Georgia Tech) in the United States, with the title 'Population Pharmacogenomics for Precision Public Health in Colombia’.
Pharmacogenomics studies the interaction of DNA with drugs to understand the variability of the response to treatment and possible side effects. This is how this article focuses on the pharmacogenomic characterization of two Colombian populations: Antioquia and Chocó. The published information dates from the premise that within DNA there are changes (mutations) that affect the metabolism of certain drugs and based on this, they discovered a number of genetic changes that were pharmacologically relevant, which can guide the pharmacological treatments of drugs such as Warfarin, Clopidogrel, and Statins in these two populations.
The importance of this research is to know those pharmacogenomic variants with relevance in these specific populations, from which new useful data could be extracted in the management of these drugs in other populations of the country.
Anha Melissa Robledo Moreno, a biologist graduated from CES University, expressed, “we are investigating the population genomics of genetic variants that mediate response to medications in an effort to inform healthcare decisions in Colombia”.
Today in our country, precision medicine remains very promising. However, these topics of genomics, personalized medicine and precision medicine remain largely unknown.
“So why work this? Because in traditional medicine all people receive similar treatments, but it must be taken into account that there are differences in certain aspects of the genetics of each individual, which means that not all respond equally, for which it is necessary to seek treatments according to DNA from each person”Stated Camila Montes Rodríguez, graduate and biologist from GenomaCES Biotechnologies at CES University.
This research was in charge of: Anha Melissa Robledo Moreno, Camila Montes Rodríguez, Wendy Vanessa Jaraba Álvarez, Sara Vélez Gómez, Isaura Torres, who belong to the GenomaCES Biotechnologies group, led by Dr Juan Esteban Gallo scientific director of this same group, together to Georgia Tech University in the United States led by Professor King Jordan's group.